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Focal segmental glomeruloscierosis in children with idiopathic
nephrotic syndrome. A report of the Southwest Pediatric
Nephrology Study Group1
Focal segmental glomerulosclerosis in children with idiopathic ne-
phrotic syndrome. A report of the Southwest Pediatric Nephrology Study
Group. Clinicopathologic correlations were examined in 75 children
with focal segmental glomeruloscierosis (FSGS) associated with idio-
pathic nephrotic syndrome. The biopsy specimens of all patients were
examined by electron microscopy (69 patients) or immunofluorescence
microscopy (67 patients) in addition to light microscopy. Fifty-three
patients (group A) had FSGS diagnosed on their first biopsy; 22 patients
(group B) had one to three previous biopsies showing minimal glomer-
ular changes or mesangial hypercellularity prior to the demonstration of
FSGS on a subsequent biopsy. Considerable homogeneity between the
diagnostic biopsy features in the two groups was evident. Diffuse
mesangial hypercellularity and 1gM deposition were found in a similar
percentage of each group, but these features did not correlate with each
other. To date, the mean duration of follow-up for the entire group has
been 57 months (range, 7 to 217 months): 21% have developed ESRD,
23% have a decreased GFR but not ESRD, 37% have persistent
proteinuria only, 11% are in remission, and 8% have been lost to
follow-up. No morphologic or clinical features have been predictive of
outcome during this relatively short period of followup. The frequency
of chronic renal failure and ESRD has been similar in groups A and B.
These data suggest that the clinical outcome in children with FSGS is
poor in many patients, whether the diagnosis is established on an initial
or subsequent renal biopsy specimen.
Glomérulosclérose focale et segmentaire chez des enfants atteints de
syndrome néphrotique idiopathique. Un rapport du Southwest Pediatric
Nephrology Study Group. Des correlations anatomo-cliniques ont eté
examinCes chez 75 enfants atteints de glomërulosclérose focale et
segmentaire (FSGS) associée a un syndrome nCphrotique. Les speci-
mens biopsies de tous les malades ont etC CtudiCes en microscopie
Clectronique (69 malades) ou en microscopie avec immunofluorescence
(67 malades) en plus de Ia microscopie optique. Cinquante-trois
malades (groupe A) avaient une FSGS diagnostiquCe a la premiere
biopsie; 22 malades (groupe B) avaient eu une a trois biopsies
antérieures indiquant des lesions glomCrulaires minimes ou une
hypercellularite mCsangiale avant Ia demonstration de Ia FSGS par une
biopsie ultérieure. Une homogCnCitC considerable entre les caractérist-
iques de Ia biopsie diagnostique Ctait Cvidente dans les deux groupes.
tine hypercellularitC mésangiale diffuse et des dépôts d'IgM ont etC
trouvés en proportion identique dans chaque groupe, mais ces
caractéristiques n'étaient pas corrClCes entre elles. A ce jour, Ia durée
moyenne du suivi du groupe entier a été de 57 mois (extremes 7 a 217
mois): 21% ont developpe une ESRD, 23% ont une GFR diminuCe mais
pas d'ESRD, 37% ont une protéinurie persistante seulement, 11% sont
en remission, et 8% ont etC perdus de vile. Aucune caractéristique
morphologique ou clinique n'a permis de prédire le devenir pendant
cette période de suivi relativement courte. La frCquence d'une insuf-
fisance rénale chronique et d'une ESRD était identique dans les groupes
A et B. Ces données suggerent que le devenir clinique de malades
atteints de FSGS est sombre chez beaucoup de malades, que le
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diagnostic soit Ctabli sur un fragment de biopsie rCnale initiale ou
ultérieure.
Focal segmental glomeruloscierosis (FSGS) is the renal histo-
pathologic lesion observed in approximately 10% of children
with idiopathic nephrotic syndrome (INS) [1—31. Although it is
well accepted that the presence of FSGS denotes a high risk of
steroid resistance in children with NS, the uncertain outcome of
such patients has prompted a number of studies to evaluate the
prognostic value of specific pathologic and clinical features.
Pathologic indicators of poor outcome that have been suggested
include mesangial hypercellularity [3—5], the relative percentage
of global versus segmental sclerotic lesions [6—9], and the
presence of segmental hyalinosis [10], FSGS on an initial versus
subsequent biopsy [11, 12], and either tubulo-interstitial [8, 13]
or vascular disease [14]. Clinical and laboratory features that
have been proposed include hypertension [9, 121, increased
levels of serum cholesterol or other lipids [14, 15], and the
presence of nephrotic syndrome [12, 16] or hematuria [5, 17,
18]. However, the data remain inconclusive despite the fact that
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Fig. 1. Light micrograph of a focal segmental lesion. This diagnostic
biopsy specimen (group B) was taken 10 years after the onset of
symptoms. (Trichrome x 500)
long-term follow-up studies have confirmed the wide variation
in the frequency of progression to chronic renal failure in
patients with FSGS [5, 7, 12, 15, 18—25].
Apart from the studies of Habib and Kleinknecht [201 and
Gubler et al [22], most of the previous reports of FSGS in
children have come from single institutions with relatively small
patient populations and have included a number of children
whose biopsy specimens were given only light microscopic
evaluation (a fact which precludes the ability to eliminate other
glomerulopathies associated with focal sclerosis, for example,
IgA nephropathy [261). In an attempt to further elucidate the
characteristics of FSGS in children in the United States,
members of the Southwest Pediatric Nephrology Study Group
(SPNSG) have compiled data on children with this disorder.
Our study includes (1) the requirement of both light microscopy
(LM) and either immunofluorescence (IF) or electron micros-
copy (EM) for entry of patients, (2) compilation of the largest
number of children with FSGS from the United States, and (3)
heterogeneous racial characteristics of the patient population.
The aims of this retrospective study were (1) to compare
pathologic features of the biopsy specimens from patients in
whom the lesion of FSGS was identified in an initial versus a
subsequent renal biopsy, (2) to describe the clinical course of
the disease in a large group of children in the United States, and
(3) to identify clinico-pathologic correlations which might aid in
predicting clinical outcome.
Methods
Patient population
Patients under 18 years of age were accepted into the study if
they had documented evidence of nephrotic syndrome (defined
according to our previously published criteria [271) and had a
renal biopsy studied by LM and either IF or EM, in which the
diagnosis of FSGS was established by SPNSG pathologists.
FSGS was defined as segmental capillary loop collapse and
increased mesangial matrix (Fig. 1) sometimes associated with
intracapillary foam cells (Fig. 2) in one or more glomeriilar tufts
[4]. Clinical or laboratory evidence of systemic disease (post-
infectious glomerulonephritis, systemic lupus erythematosus,
Henoch-Schonlein purpura, IgA nephropathy, diabetes mel-
Fig. 2. Light micro graph of a focal segmental lesion with an intracapil-
lary foam cell (arrow). The biopsy specimen (group A) was taken 2.5
months after the onset of symptoms. (Trichrome x500) The inset
shows a foam cell at a higher magnification. (x 1250)
litus, heroin abuse, and chronic hypertension) or anatomic
disorders (reflux nephropathy, unilateral renal agenesis) ex-
cluded patients from the study.
Clinical and laboratory studies
After FSGS was confirmed, the clinical records of each
patient accepted into the study were reviewed by physicians at
the participating centers. Complete information for all clinical
variables, however, was not available for every patient. Hyper-
tension, proteinuria, and hematuria were defined as in previous
studies [27], and glomerular filtration rate (GFR) was assessed
by measurement of endogenous creatinine clearance or esti-
mated by the serum creatinine-length equation of Schwartz et al
[28]. A decreased GFR was defined as less than 90 ml/min!l.73
m2.
Response of NS to steroid therapy was defined as the loss of
proteinuria as assessed by dipstick. Steroid-dependent re-
sponses were included. Owing to the retrospective nature of the
study, no attempt to standardize prednisone dosage schedules,
duration of therapy, or the use of adjuvant therapy was carried
out. The consequent variation in treatment regimens made it
difficult to reach conclusions about specific responses to
therapy.
Pathology studies
Renal tissue samples were prepared in the individual institu-
tions using methods described in our previous studies [27, 29].
Renal biopsy specimens from 134 patients with INS and sus-
pected FSGS were reviewed by pathologists from the partici-
pating institutions, following which a mean of four selected
slides were re-examined by two principal SPNSG pathologists
to confirm the presence of a diagnostic lesion. Questionable
cases were submitted to all group pathologists for a consensus
opinion. Seventy-five patients were accepted into this study,
representing 7.1% of the 1053 biopsies performed on patients
with NS during the period of study. Once a case was accepted,
all previous and subsequent renal biopsy specimens from that
patient were reviewed. Fourteen patients had followup biopsies
after the diagnostic biopsy. The total number of biopsies for the
group as a whole was 116. For diagnostic biopsy specimens, the
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Table 1. Comparison of initial clinical and laboratory features in patients with focal segmental glomeruloscierosis diagnosed on first or
subsequent biopsy
Ageal)
years
Duration of clinical
disease before
diagnostic biopsya
months
Quantitative
proteinuriaa
g/24 hr
Microscopic
hematuria
%
Serum
albumina
g/dl
Serum
Cr mg/dl
C BP
%
FSGS diagnosed on
first biopsy
(Group A) N = 53 8.7 4.6 12.7 19.5 4.2 4.2 60 2.2 1.0 0.7 0.4 34
FSGS diagnosed on
subsequent biopsy(Group B) N = 22 10.2 4.6 59.5 48.3 6.3 3.5 53 1.5 0.9 0.7 0.3 43
P NS 0.002 NS NS 0.01 NS NS
Abbreviations: FSGS, focal segmental glomerulosclerosis; Cr, creatinine; BP, blood pressure.
a Mean values I sr are represented.
b The age given was age at the time of the diagnostic biopsy.
12
Mean age
10 (years)
Females 9.7
Males 5.8
a 8 Combined 7.7
(0
1 lIjinIr
Age at onset, years
Fig. 3. Age at onset of symptoms and sex distribution of patients with
the idiopathic nephrotic syndrome and focal segmental glomerulo-
sclerosis. The graph excludes four patients (2 males, 2 females) whose
age at the onset of symptoms was not recorded. Symbols are: El,
females; •, males.
mean number of glomeruli examined per slide was 25, and for
the earlier, nondiagnostic biopsy specimens, the mean number
of glomeruli examined was 26.
Individual LM, IF, and EM features were examined
semiquantitatively by methods described previously [27, 291. In
the LM studies, mesangial prominence was graded by a modi-
fication of the method of Murphy, Jukkola, and Roy as we have
described previously [27]. Hilar prominence was defined as
greater than 8 2 cells in the juxtaglomerular apparatus or
increased matrix at the vascular pole. Hyalinosis was defined as
eosinophilic homogeneous material on the inner aspect of a
peripheral glomerular capillary loop—usually associated with a
sclerotic tuft, but also occurring occasionally in an otherwise
unremarkable glomerulus [4]. Visceral epithelial caps were
defined as swelling and proliferation of visceral epithelial cells
over the foci of sclerosis. Arteries and arterioles were evaluated
by LM for thickening of the wall and/or intima. IF and EM
findings were compiled as previously described [29].
Statistical methods
Correlations were sought between clinical and pathologic
features. Statistical methods utilized included Student's t tests
for comparison of means, Spearman correlation testing for the
ordinal variables, and x2 contingency table analysis or Fisher's
exact probability test for the association of categorical vari-
ables. Statistical significance was defined as a P value equal to
or less than 0.05. Results are given in the text and tables as
mean 1 SD.
Results
Seventy-five children (mean age, 7.7 years at the time of
clinical presentation of renal disease) were accepted into the
study (Fig. 3). All 18 cases of FSGS in children less than 3 years
of age occurred in boys, whereas beyond that age the frequency
in the two sexes was similar. Thirty-two patients were white;
thirty, black; eleven, hispanic; one, Indian; and one, of un-
known racial background. The patients were separated into two
groups: In 53 patients (group A) the diagnosis of FSGS was
made on the initial renal biopsy; in the other 22 (group B) the
diagnostic biopsy was preceded by one to three biopsy speci-
mens showing only minimal change disease or mesangial
hypercellularity.
Clinical presentation
Nephrotic syndrome was present initially in 57 of 73 patients
(78%). Sixteen of the patients presented with only asympto-
matic proteinuria, but all developed the nephrotic syndrome at
some time during their clinical course. Hypertension was noted
in 36% of the patients, and although microscopic hematuna was
present in 57%, an episode of gross hematuria was observed in
only one patient. Estimated GFR was decreased in 30 of the 62
patients (48%) for whom this information was available. Other
than a slightly lower serum albumin concentration in group B,
clinical and laboratory features at presentation (Table 1) did not
differ between groups A and B.
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Tubulointerstitial
disease
Hilar prominence
Visceral epithelial
caps
Focal mesangial
hypercellularity
Hilar prominence
mod-severe
Diffuse mesangial
hypercellularity
_______(all grades(
Diffuse mesangial
hypercellularity(2+-3+(
Vascular wall
________
thickening
Pathologic findings
Initial and diagnostic biopsies. Initial renal biopsies in each
group were performed at a mean of approximately 1 year after
clinical presentation (group A, 12.4 months; group B, 12.1
months). These were the diagnostic biopsies for group A,
whereas the diagnostic biopsies for group B were performed a
mean of 59.5 months from onset of symptoms.
LM studies were performed on all renal biopsy specimens.
Since the frequency of specific LM features in the diagnostic
biopsy specimens of groups A and B was similar, we have
depicted selected pathologic findings from the entire group in
Figure 4. Glomerular intracapillary foam cells were present in
60% of diagnostic biopsies in group A and 45% in group B (P =
0.35). Renal biopsy specimens without visceral epithelial caps
had focal sclerotic lesions which were attached to Bowman's
capsule by synechiae or dense adhesions.
When the frequency of pathologic features in the entire group
was compared between diagnostic and nondiagnostic biopsy
specimens, it was found that hyalinosis was noted in 50% of the
specimens exhibiting FSGS but was also seen in 2 of 22 biopsy
specimens without demonstrable focal sclerosis. In these two
biopsy specimens the hyalinosis occurred near the vascular
pole and was not associated with segmental sclerosis. Mild
arteriolar wall thickening was seen in ten diagnostic biopsy
specimens (13%) but not in nondiagnostic ones.
IF studies revealed one or more immunoreactants in 51 of 67
patients evaluated. Glomerular 1gM, seen in 34 of 56 biopsy
specimens studied (61%), had a pattern of distribution that was
diffuse mesangial in 14, focal segmental in 18, and nonspecified
in two biopsy specimens. C3 accompanied 1gM in 23 biopsy
specimens and was present alone or with an immunoreactant
other than 1gM in eight. Twenty-five patients with diffuse
mesangial hypercellularity (DMH) were studied for the pres-
ence of 1gM; only five showed diffuse mesangial 1gM staining.
Thus, there was a poor association between diffuse 1gM staining
and DMH. The presence of hyalinosis by LM was associated
with C3 (P = 0.03), most often focal, segmental, but not with
1gM. Staining for IgG and IgA was present in 14 and 7 biopsy
specimens, respectively. In no case was IgA dominant or
codominant. No significant differences were seen in IF findings
between groups A and B.
EM studies were performed on 69 biopsy specimens, but only
22 (32%) had segmental sclerotic lesions in the glomeruli
available for EM. Sixty-two biopsy specimens (90%) had some
degree of glomerular endothelial cell swelling. All biopsy speci-
mens had effacement of visceral epithelial cell podocytes, but
this change was diffuse in only 36 (53%). Fifty-five biopsy
specimens (79%) had visceral epithelial cell swelling or
vacuolization. Sixteen diagnostic biopsy specimens (21%) con-
tained electron dense material, which was observed in regions
of hyalinosis in ten, discrete within the mesangial matrix and
suggestive of "immune-type" deposits in five, and in both areas
in one biopsy specimen. The lamina rara interna of the glomer-
ular basement membrane was focally widened in 60 specimens
(87%). Ultrastructural findings of diagnostic biopsy specimens
were not different between groups A and B.
Follow-up biopsies. Fourteen follow-up biopsies (eight in
group A, six in group B) were performed at a mean of 37.5
months after the diagnostic biopsy. Of the 14 biopsy specimens,
hyalinosis was first identified in the follow-up biopsy in six
patients, whereas in three others it was present in the diagnostic
biopsy but not in the follow-up biopsy. The percentage of
segmentally sclerotic glomeruli showed no consistent trend in
follow-up biopsy specimens, but in 9 of the 14 cases, the
percentage of globally sclerotic glomeruli increased substan-
tially from a mean of 7% in diagnostic biopsies to 51% in
follow-up biopsies (P = 0.02). Tubulointerstitial disease, which
was present to some degree in the diagnostic biopsies of all 14
patients, was the same or increased in severity in all but one
follow-up biopsy. DMH, which had been present in nine
diagnostic biopsies from this group, was present in five follow-
up biopsies. In two of these, the severity was decreased, in two,
the same, and in one, increased.
Clinical course and outcome. For the total group, the mean
duration of follow-up was 57 months (range, 7 to 217 months)
from the onset of symptoms. The latest evaluation revealed that
21% have endstage renal disease (ESRD), 23% have decreased
GFR but not ESRD, 37% have persistent proteinuria, 11% have
remission of INS, and 8% have been lost to followup. Analysis
Fig. 4. Frequency of selected morphologic
features in the diagnostic biopsy specimens of
75 children with focal segmental
glomeruloscierosis.
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Table 2. Comparison of latest clinical and laboratory features in patients with focal segmental glomerulosclerosis diagnosed on first or
subsequent biopsy
Agea
years
Duration of
follow-up
months
BP
%
Hematuria
%
GFR
mllmin/1.73 m2
GFRb
%
ESRD
%
FSGS diagnosed on
first biopsy
(Group A) 11.6 5.5 45 39 22 17 123 99 39.2 22
FSGS diagnosed on
subsequent biopsy
(Group B) 14.3 5.6 101 62 56 20 114 44' 61.9 23
P NS 0.003 0.02 NS NS NS NS
Abbreviations: ESRD, endstage renal disease; FSGS, focal segmental glomerulosclerosis; GFR, glomerular filtration rate; BP, blood pressure.
a Mean values 1 SD are represented.
b The values include patients with ESRD.
The data presented are from the time of clinical presentation.
of only those patients with greater than 2 years followup (49
patients) revealed data which are not different from those
described for the whole group. To date, 7 of the 16 patients who
developed ESRD have received renal transplants. Five of these
patients have subsequently died, one returned to dialysis after
rejection, and one has been nephrotic (10 g proteinurialday). Of
five transplanted kidneys which have been examined morpho-
logically, only one demonstrated recurrent FSGS. Of the re-
maining nine patients who progressed to ESRD, eight have
been maintained on dialysis, and one has died.
Group B patients were followed significantly longer than
group A patients (Table 2), but the mean period of followup
after the diagnostic biopsy (group A, 32.8, months; group B,
37.9 months) was not significantly different. The percentage of
patients with decreased GFR and ESRD was found to be similar
in groups A and B. Group A patients progressing to ESRD
developed symptoms at a mean age of 7.3 years and ESRD
occurred after a mean followup of 67 months. Group B patients
who progressed to ESRD were younger at the onset of disease
(mean age, 2.9 years) and ESRD tended to occur after longer
followup (mean, 114 months).
To examine the possibility that group A patients might do
worse over a longer period of time, we also compared 18 group
A patients and 12 group B patients who had followup periods of
more than 4 years. Mean followup did not differ for these two
subgroups (group A, 88 months; group B, 123 months; P> 0.2)
and the outcome was not significantly different: Nine patients
(50%) in group A and seven patients (58%) in group B had
decreased GFR while six (33%) group A patients and three
(23%) group B patients developed ESRD.
Clinical features as outcome indicators
Hypertension at onset did not show a significant correlation
with decreased GFR at followup, although 57% of patients with
hypertension at onset developed decreased GFR compared to
35% who were normotensive initially (P = 0.29). Hypertension
at the latest evaluation was present significantly more fre-
quently in group B than in group A patients (Table 2); in those
followed more than 4 years, hypertension was still more com-
mon in group B (70%) than group A (29%) (P < 0.002).
Neither the presence of hematuria nor the severity of protein-
usia at onset was a significant factor predicting outcome.
Hematuna was present initially in 75% of patients who later
developed ESRD and in 52% of patients who did not (P 0.25).
Of the 16 patients who presented with only asymptomatic
proteinuria, eight developed decreased GFR and three of these
progressed to ESRD.
Response to treatment—relationship to subsequent outcome
Prednisone was prescribed for 56 patients (38 in group A, 18
in group B). Nine patients (24%) in group A and seven (39%) in
group B responded to steroid therapy at some time (P = 0.34).
Response to therapy given prior to the initial biopsy was
significantly different between the two groups; only 15% (4 of
26) of group A patients who were given pre-biopsy steroids
responded, whereas 60% (6 of 10) of group B patients re-
sponded (P = 0.014). The postdiagnostic biopsy response,
however, was not different; 26% (9 of 35) of group A patients
and 19% (3 of 16) of group B patients responded (P = 0.73).
Response to corticosteroids did not predict outcome. Sixteen
of 56 patients who received corticosteroids responded. The
outcome for these 16 patients was no different from that of the
group as a whole. Six patients developed decreased GFR (two
had ESRD), eight had persistent proteinuria, and two were
asymptomatic at latest follow-up.
Clinico-pathologic correlations
DMH tended to be observed more frequently in biopsy
specimens taken early in the clinical course of the disease, and
often was not present in follow-up specimens. The sex distribu-
tion of patients with DMH was similar to that of the group as a
whole (20 males; 9 females). Four children with DMH were less
than 2 years of age at presentation. Three of these children had
normal renal function without proteinuria after 10 to 28 months
of followup. The fourth child had moderately decreased GFR
(30 to 60 mllmin!1 .73 m2) after 115 months of disease. The
relationship of DMH to the time of biopsy and renal function at
follow-up is shown in Table 3. Fifteen of the 16 patients who
progressed to ESRD had no or only mild DMH, and no patient
developing ESRD had severe DMH. There was no significant
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Table 3. Latest clinical status of 75 children with focal segmental glomerulosclerosis—relationship to degree of diffuse mesangial
hypercellularity
Degree of
DMH
Number
of patients
Age at
onset
years
Clinical
onset to
biopsy
months
Clinical
onset to
followup
months
Current status of patients (% of group)a
Complete
remission
Isolated
proteiniria GFR ESRD
None (0) 46 7.4 26.4 58.8 8 44 24 24
Mild (1+) 15 6.1 31.1 70.8 14 28 22 36
Moderate (2+) 10 7.3 9.0 48.0 20 40 30 10
Severe (3+) 4 6.9 7.0 42.0 25 50 25 0
Abbreviations: DMH, diffuse mesangial hypercellularity; ESRD, endstage renal disease; GFR, glomerular filtration rate.
a The group represents patients for whom clinical data were available.
difference between outcomes for children with DMH who were
less than 6 years of age versus those older than 6 years.
Glomerular hyalinosis tended to be more frequent in the
initial biopsy specimens of patients who subsequently devel-
oped renal failure, although this was not statistically significant.
However, when follow-up biopsies were included in this analy-
sis, hyalinosis was present significantly more often in speci-
mens of patients with renal failure (72%) than in those of
patients with a normal GFR (48%; P = 0.05). Biopsy specimens
were taken from patients with glomerular capillary foam cells
(GFC) a mean of only 19 months after the onset of symptoms
while those without GFCs were symptomatic for 35 months
before biopsy (P = 0.04). This correlation is compatible with
the observation that GFCs tended to be more common in
group A biopsy specimens, although this was not statistically
significant.
The presence of tubular atrophy or interstitial fibrosis was
associated with a longer duration of clinical disease prior to
biopsy (28 months vs. 8 months, P = 0.06). A similar relation-
ship existed for the presence of interstitial foam cells (IFC) [65
months for patients with IFC vs. 19 months for patients with no
IFC (P = 0.05)]. Tubulointerstitial disease (TID) was seen more
frequently in the biopsy specimens of patients who subse-
quently developed chronic renal failure, but this association did
not reach statistical significance, even when the analysis was
limited to specimens exhibiting moderate to severe TID.
Nine of the 14 patients who had followup biopsies developed
decreased GFR. Eight of these nine had markedly increased
percentages of globally sclerotic glomeruli on the followup
biopsy, compared to patients who maintained a normal GFR (P
= 0.02). The mean duration from diagnostic biopsy to followup
biopsy was similar for both groups, but the groups are quite
small, making statistical evaluations suspect.
Hypertension was present in 17 of 52 (33%) patients at
followup. No correlation was found between hypertension and
the percentage of glomeruli with either segmental or global
sclerosis. Only two of ten patients with documented arterial or
arteriolar sclerosis had hypertension at followup.
Discussion
The present study confirms the poor prognosis of FSGS and
INS reported previously in children with relatively homogene-
ous racial characteristics. However, in our multicenter evalua-
tion of a heterogeneous group of children with FSGS, we have
not been able to identify any clinical or pathologic features of
prognostic significance in this condition. More specifically, we
found that children in whom FSGS is documented on initial
renal biopsy appear to have a similar lesion and prognosis to
those with FSGS identified on a later biopsy.
The patient population in the present study was derived
initially from children with documented nephrotic syndrome in
whom FSGS was observed in a renal biopsy. By definition we
have therefore excluded a number of patients who had focal
sclerotic lesions but no evidence of nephrotic syndrome. It
should be noted that during a 10-year period from 1972 to 1981,
our group performed a total of 2929 renal biopsies. Of these,
1053 were in children with nephrotic syndrome. Hence, the 75
patients who showed the lesion of FSGS represented 7.1% of
the total number of children with NS. However, since most of
the children with INS in our centers are not biopsied, this
apparent frequency rate probably overestimates the incidence
of FSGS in children with INS.
Morphologic studies, which showed no differences in patho-
logic features between biopsy specimens of patients who did
and did not develop a decreased GFR, suggested that mesangial
hypercellularity, visceral epithelial caps, synechiae, hilar prom-
inence, and tubulointerstitial disease were part of the spectrum
of FSGS and not correlated with clinical severity of disease.
However, an increase in the percentage of globally sclerotic
glomeruli from diagnostic to followup specimens correlated
with the development of decreased GFR (P = 0.02). This
finding agrees with the observations of Velosa, Donadio, and
Holley [91 and Saint-Hillier et al [181. The number of patients
with follow-up biopsies who did not have a decreased GFR was
so small, however, that this correlation may not be valid. When
followup and diagnostic biopsies were considered together,
hyalinosis also correlated with decreased GFR (P = 0.05).
Diffuse mesangial hypercellularity has been cited as an indi-
cator of a poor prognosis by Gubler et al [22]. We were unable
to confirm this observation, as were Brown et al [14] and White,
Glasgow, and Mills [301. In fact, while patients with moderate
to severe DMH comprised only 20% of the patients in our
study, 38% of the patients in remission came from this group,
and no patient who developed ESRD had marked DMH (Table
3). In our study, DMH was less frequent in patients with clinical
disease of long duration, suggesting that the mesangial
hypercellularity was an early response. These findings agree
with those of Newman et al [23] who reported a similar decrease
in cellularity in FSGS with time, although some authors [5, 22]
have reported the persistence of DMH in repeat biopsies.
Diffuse glomerular 1gM in the presence of DMH has also been
cited as predicting a poorer prognosis in patients with INS [31],
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but we found no relationship between the presence of 1gM and
DMH. Furthermore, there was no correlation between the
presence of 1gM and the progression to renal failure. We have
no explanation for some of the differences between our patients
and those in the literature, although genetic factors [32] may be
important in understanding these differences. Our patients
represented a heterogeneous population with a high proportion
of black and hispanic children compared to the more homogene-
ous English and French populations reported previously [12,
22].
It has also been suggested that the presence of vascular
changes [7, 14] is indicative of a poor prognosis and a tendency
to develop hypertension. We looked specifically at this relation-
ship and found no correlation. Platelet thrombi and arteriole
and arteriolar thickening, which have been cited by others [33,
34] as evidence for a primary vascular lesion, were too in-
frequent and randomly distributed to be helpful.
The suggestion that children in whom FSGS is documented
on an initial renal biopsy have the worse prognosis [11, 12] was
not substantiated by the results obtained in this study. Fol-
lowup renal function was similar in groups A and B, and
although group B patients were followed longer from the time of
clinical presentation, the time from diagnostic biopsy to last
followup visit was the same for both groups. In addition, there
was no difference in renal function when patients in groups A
and B were followed for more than 2 or 4 years, so the
frequency of renal failure in group B was not a reflection of the
longer followup period. However, group B children did take
twice as long from onset of symptoms to develop ESRD and
were significantly younger at onset of INS.
The only clinical difference between groups A and B patients
was the more frequent occurrence of hypertension at followup
in group B, even when only groups A and B patients with an
equal duration of clinical disease were compared. It is possible
that the increased frequency of hypertension in group B was
related to the dosage or duration of corticosteroid therapy, but
the clinical data were not adequate to test this hypothesis. An
alternate possibility is that hypertension itself was involved in
the development of focal sclerotic lesions in the group B
patients.
In summary, this study shows: (I) children in the southwest-
ern United States are no more likely to develop chronic renal
failure if the diagnostic lesion of FSGS is demonstrated on an
initial rather than a subsequent renal biopsy, (2) a greater
percentage of children with a nondiagnostic first biopsy (group
B) have hypertension at followup; (3) an increase in the
percentage of globally sclerotic glomeruli in the follow-up
biopsy correlates with the development of chronic renal failure;
(4) neither DMH nor the presence of 1gM in a diffuse mesangial
pattern predict a poorer outcome. Although additional followup
of these patients will be necessary to confirm our current
observations, it would seem reasonable to conclude that FSGS
in association with INS portends a poor prognosis in a high
percentage of patients—irrespective of whether the lesion was
identified on the first or subsequent biopsy specimen of the
patient—but that specific outcome indicators for individual
patients remain elusive at the present time.
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